Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

Clinical trial NCT07086456 · RECRUITING

Trial details

NCT number: NCT07086456
Sponsor: Sun Yat-sen University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Surufatinib Tislelizumab Concurrent Chemoradiotherapy Consolidation Therapy Non-small Cell Lung Cancer

Start date: 2025-07-20
Primary completion: 2029-07-19
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.